Cardiogeni PLC - Completion Share Exchange Agreement Issue Equity
Cardiogeni PLC
("Cardiogeni", "CGNI" or the "Company")
Completion of Share Exchange Agreement with Kira Health Invest AG and Issuance of Equity
Cardiogeni (AQSE: CGNI), a
The following conditions of completion have been duly met, which include:
· Transfer of 1,308,444 shares in Cell Therapy Limited from Cardiogeni to Kira representing 67.5% of its total share capital. Cardiogeni will retain shares in Cell Therapy Limited representing 32.5% of its total share capital.
· Transfer of 3,250 of the existing shares of Lumen Clinics B.V. from Kira to Celixir Limited, a wholly owned subsidiary of Cardiogeni, representing 32.5% of its total share capital
· Cardiogeni and Kira have entered a shareholders agreement with Kira that defines the forward management, operational plan and governance of Cell Therapy Limited.
· Receipt of loan guarantor letter from Kira's principal investor for the remaining
The intial tranche of
The Transaction completes the formation of, and provides funding for, United Arab Emirates Joint Venture ("
As stated in 2025 announcements, the JV will undertake the clinical development and commercialisation of heart medicines in the GCC (Gulf Cooperation Council) region. CLXR-001 is the lead product which successfully completed an EU Phase IIa clinical trial showing a statistically significant (P<0.05) improvement in heart failure. Phase 2b/3 clinical trials are planned in the GCC in 2026/27.
Issuance of shares
Further to the announcement dated
Additionally, the Company announces it has agreed to satisfy an invoice for professional services rendered by an adviser through the issue of 260,000 new ordinary shares of 1p each in the Company.
Further to the announcement dated
Accordingly, application will be made for the 8,330,961 new ordinary shares, which will rank pari passu with the existing ordinary shares in issue, to be admitted to trading on the AQSE Growth Market ("Admission"). It is expected that Admission will take place at or around
Total voting rights
Following Admission, the Company confirms that its total issued share capital will consist of 97,434,717 Ordinary Shares, with one voting right per Ordinary Share. The Company holds 1,280,000 Ordinary Shares in treasury. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company pursuant to the FCA's Disclosure Guidance and Transparency Rules.
Following the issuance of new ordinary shares to the Directors, the Directors holdings are as follows:
|
Name |
Number of ordinary shares |
Holding |
|
Ajan Reginald (via personal holding and that of his spouse |
28,104,441 |
28.84% |
|
Dr. Darrin M Disley OBE |
3,816,064 |
3.92% |
|
Professor |
16,855,254 |
17.30% |
|
|
876,140 |
0.90% |
|
Lord |
100,000 |
0.10% |
|
|
250,000 |
0.26% |
Dr Darrin M Disley OBE, Executive Chairman of Cardiogeni commented:
"I am delighted that we have been able to complete on a transaction that is transformational to the Company and its shareholders. We now have sufficient funding to complete a pivotal Phase 2b clinical trial and to potentially gain market approval for its heart failure medicine CLXR-001 in the gulf cooperation council (GCC) countries. A successful result from the trial would represent a significant value inflection point for shareholders via the ability to market the medicine to a significant customer base with a clear unmet clinical need and then execute a global out-licensing or trade sale strategy to crystalize shareholder returns."
ENDS
The directors of Cardiogeni accept responsibility for this announcement.
For further information please contact:
|
Cardiogeni PLC |
|
|
Dr Darrin M Disley, Executive Chairman Ajan Reginald, Executive Officer |
Via First Sentinel |
|
First Sentinel Corporate Finance Limited, Corporate Adviser |
|
|
|
+44 (0) 7858 888007 |
|
SP Angel Corporate Finance LLP, Corporate Broker |
|
|
|
+44 20 3470 0470 |
About Cardiogeni
Founded by Nobel Laureate, Professor
The Group's lead product, CLXR-001, is a patented engineered cellular medicine to treat heart failure patients which is administered during coronary artery bypass grafting surgery. The Group's novel epigenetic cellular reprogramming technology was developed in-house by Professor
CLXR-001 targets heart failure which will affect 1 in 4 people in their lifetime and is not reversible or curable. CLXR-001 consists of a novel allogeneic (off-the-shelf) cell type, iMP cells, engineered for cardiac regeneration whose mechanism of action is to regenerate damaged heart tissue and restoration of improved heart function improving both the life expectancy and quality of life of patients.
CLXR-001 targets the cardiac market niche of CABG surgery with ~400,000 patients per year in the US alone. The Group's two follow-on products target larger cardiac market segments of stent treatment (over two million patients per year) and myocardial infarction (heart attack, over one million patients per year). Each of the products has the potential to become a first or best-in-class blockbuster (
CLXR-001 has successfully completed an EU Phase 2 investigator sponsored clinical trial in which patients showed a statistically significant (P<0.05) improvement in all end-point targets including heart function, reduction in heart scarring and an improvement in quality of life.
CLXR-001 has received regulatory approval to begin a randomized controlled trial from the national regulatory authority of a European Union member country, and this trial has begun dosing patients with interim data expected to read-out within 30 months of Admission.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.
Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.
This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.
In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.
The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.
Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
FOR OUR FULL DISCLAIMER CLICK HERE